Table 1.

Effect of Inhibitors on the Expression of Apoptosis and Proliferation Markers in Normal and Paramalignant Human Urothelial Cells

Cell LineMarker0.1% (v/v) DMSO (%)1 μmol/L PD153035 (%)5 μmol/L U0126 (%)5 μmol/L LY294002 (%)20 μmol/L 15dPGJ2 (%)
NHUCleaved caspase-3<1<1<1<158.8
Cleaved CK18<1<1<1<149.7
Ki6768.311.612.631.317.5
HU-p53DDCleaved caspase-3<1<1<1<158.3
Cleaved CK18<1<1<1<148.6
Ki6761.721.310.929.216.6
HU-CDK4mutCleaved caspase-3<1<1<1<156.5
Cleaved CK18<1<1<1<148.1
Ki6756.28.99.426.812.1
  • NOTE: Immunofluorescence labeling was done on mock-transduced NHU, HU-p53DD, and HU-CDK4mut cells after 3-day treatments with 0.1% (v/v) DMSO (vehicle-only control), 1 μmol/L PD153035, 5 μmol/L U0126, and 5 μmol/L LY294002 or after a 24-h treatment with 20 μmol/L 15dPGJ2 (positive control). The mean percentage of cells expressing cleaved caspase-3, cleaved CK18, or Ki67 is shown. Each data point is the mean from three replicate fields, and results are representative of duplicate experiments using two independently transduced NHU cell lines. Note the low levels of expression of the apoptosis markers, except in cells treated with 15dPGJ2, and reduced expression of the proliferation marker after treatment with any of the inhibitors compared with the vehicle-only control.